Ignite Creation Date:
2024-05-06 @ 7:24 PM
Last Modification Date:
2024-10-26 @ 3:06 PM
Study NCT ID:
NCT06004128
Status:
NO_LONGER_AVAILABLE
Last Update Posted:
2024-06-03
First Post:
2023-08-18
Brief Title:
Provide Pre-approval Single-patient Expanded Access Compassionate Use of VYD222 for Patients With Symptomatic COVID-19 Refractory to Other Treatments
Sponsor:
Invivyd Inc
Organization:
Invivyd Inc
Study Overview
Official Title:
Provide Pre-approval Single-patient Expanded Access Compassionate Use of VYD222 for Patients With Symptomatic COVID-19 Refractory to Other Treatments
Status:
NO_LONGER_AVAILABLE
Status Verified Date:
2024-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Provide pre-approval single-patient Expanded Access Compassionate Use of VYD222 for patients with symptomatic COVID-19 refractory to other treatments
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None